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Abstract Increased vascular stiffness, endothelial
dysfunction, and isolated systolic hypertension are
hallmarks of vascular aging. Regular cocoa flavanol
(CF) intake can improve vascular function in healthy
young and elderly at-risk individuals. However, the
mechanisms underlying CF bioactivity remain large-
ly unknown. We investigated the effects of CF in-
take on cardiovascular function in healthy young
and elderly individuals without history, signs, or
symptoms of cardiovascular disease by applying
particular focus on functional endpoints relevant to
cardiovascular aging. In a randomized, controlled,
double-masked, parallel-group dietary intervention
trial, 22 young (<35 years) and 20 elderly (50–
80 year) healthy, male non-smokers consumed either
a CF-containing drink (450 mg CF) or nutrient-
matched, CF-free control drink bi-daily for 14 days.
The primary endpoint was endothelial function as
measured by flow-mediated vasodilation (FMD).
Secondary endpoints included cardiac output, vascu-
lar stiffness, conductance of conduit and resistance
arteries, and perfusion in the microcirculation.
Following 2 weeks of CF intake, FMD improved
in young (6.1±0.7 vs. 7.6±0.7 %, p<0.001) and
elderly (4.9 ± 0.6 vs. 6.3 ± 0.9 %, p< 0.001).
Secondary outcomes demonstrated in both groups
that CF intake decreased pulse wave velocity and
lowered total peripheral resistance, and increased
arteriolar and microvascular vasodilator capacity,
red cell deformability, and diastolic blood pressure,
while cardiac output remained affected. In the elder-
ly, baseline systolic blood pressure was elevated,
driven by an arterial-stiffness-related augmentation.
CF intake decreased aortic augmentation index
(−9 %) and thus sys to l i c b lood pres sure
(−7 mmHg; Clinicaltrials.gov: NCT01639781). CF
intake reverses age-related burden of cardiovascular
risk in healthy elderly, highlighting the potential of
dietary flavanols to maintain cardiovascular health.
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Introduction
The mechanisms underlying vascular aging are largely
unknown but involve all segments of the arterial vascu-
lar system. Hallmarks of vascular aging are not entirely
identical to those of atherosclerosis, but increasing age is
associated with endothelial dysfunction and vascular
stiffening, as well as isolated systolic hypertension,
and a substantial excess of cardiovascular mortality
(Kaess et al. 2012). Due to increased arterial stiffness,
older humans exhibit an increased pulse wave velocity
(PWV). In young individuals, the reflected pulse wave
returns to the heart and increases pressure during dias-
tole and therefore contributes to the Bwindkessel effect^
(i.e., elastic reservoir) of the aorta. In older individuals,
the pulse wave propagates faster as compared to the
young, and its return to the heart coincides with the
systolic forward flow, thus leading to aortic augmenta-
tion of systolic blood pressure (SBP; Fig. 1).
Furthermore, stiff arteries are characterized by a de-
creased absorption of the pulse wave, resulting in in-
creasedmechanical stress on the arterioles, which in turn
is thought to cause damage to the microvasculature,
leading to structural microvascular remodeling and
rarefication (Mitchell 2008). In addition to an increased
peripheral total resistance, age-dependently reduced mi-
crocirculatory perfusion, systemic endothelial dysfunc-
tion, and intimal hyperplasia are observed in elderly
subjects (Celermajer et al. 1994; Rossi et al. 2002).
There is great interest in dietary interventions to slow
or even reverse the complex pattern of these age-
associated vascular alterations, which increase cardio-
vascular risk (Shai et al. 2010).
Diet is a major determinant of healthy aging, and
certain bioactives may be capable of contributing to
the maintenance of health, thus extending a healthy life
span (Estruch et al. 2013; Williamson et al. 2009).
Flavanols, a subgroup of dietary plant-derived bioac-
tives, have gained increasing attention, as clinical die-
tary interventions have shown that a higher intake of
flavanol-containing foods can increase arterial function
in individuals at risk for cardiovascular disease (CVD),
and in those with established CVD (Heiss et al. 2003;
Heiss et al. 2010b). Although the mechanisms of action
underlying the biological effects of flavanols are not
completely understood, flavanols are one of few bioac-
tives today, for which causality between the dietary
intake and an improvement in arterial function has been
established (Loke et al. 2008; Schroeter et al. 2006).
Whether or not the intake of cocoa flavanol (CF) has the
potential to improve cardiovascular function in healthy
elderly individuals or to reverse age-related vascular
dysfunction has not been specifically evaluated thus far.
The FLAVIOLA research project, funded by the
European Union’s 7th framework program, was created
to develop the BTargeted delivery of dietary flavanols
for optimal human cell function: Effects on cardiovas-
cular health.^ In order to understand the hemodynamic
mechanisms that underlie the potential CF-intake-
mediated reversal of age-associated changes in circula-
tory function, the present FLAVIOLA AGE study aims
at elucidating in great detail the effects of cocoa
flavanols in healthy individuals. We therefore studied
in young and elderly healthy individuals the effect of a
dietary CF intervention on hallmarks of cardiovascular
aging in all segments of the cardiovascular system, such
as cardiac performance, endothelial dysfunction, in-
creased systolic blood pressure, vascular stiffness, and
microcirculatory functions.
Material and methods
Study participants and study design
We recruited YOUNG (<35 years) and ELDERLY (50–
80 year) healthy male Caucasian adult subjects without
history, signs, or symptoms indicative of cardiovascular
disease, including previous myocardial infarction,
stroke, and peripheral artery disease or current or previ-
ous medication (Fig. 2). Participants were randomly
assigned to either the CF intake group (FLAVANOL;
450 mg total flavanols two times daily) or a nutrient-
matched CF-free group (CONTROL) based on a dou-
ble-masked, parallel-group study design. All interven-
tions were provided in anonymized sachets. Study par-
ticipants were instructed to prepare the drinks by emp-
tying the contents of each packet into ∼500 ml of water;
drinks were prepared just prior to consumption. Drinks
were consume two times per day, one beverage in the
morning with breakfast and one with the evening meal.
This regimen was maintained for 14 days, with compli-
ance assessed by the collection of empty sachets on the
last study day visit.
Measurements were taken fasted before (baseline)
and 1 h after the first drink on day 1 and day 14.
Endothelial function (primary end point) was measured
as flow-mediated vasodilation (FMD). Secondary
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Fig. 1 a Schematic of cardiovascular system and b physiological
parameters reflecting basic components of the cardiovascular sys-
tem. Cardiac function is determined by heart rate (HR), cardiac
output (CO), stroke volume (SV), and total peripheral resistance
(TPR); the aorta as an elastic artery is characterized by its
physicomechanical properties: central blood pressure (BP), pulse
wave velocity (PWV), and augmentation index (AIX); conduit
artery function is determined by flow-mediated and
nitroglycerin-mediated vasodilation (FMD and NMD, respective-
ly) as well as peripheral blood pressure that can be determined at
the upper arm and finger; arteriolar conductance is characterized
by forearm blood flow (FBF), cutaneous capillary blood flow by
laser Doppler perfusion imaging (LDPI), and blood rheology by
red blood cell (RBC) deformability
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endpoints included measures of cardiac output, the
physicomechanical properties of the large conduit arter-
ies, the dilatory capacity and tone of resistance arteries,
and perfusion in the microcirculation (Fig. 1). Tertiary
endpoints included total plasma epicatechin metabolites.
The study protocol was approved by the ethics commit-
tee of the Heinrich-Heine-University; all subjects gave
written informed consent (Clinicaltrials.gov:
NCT01639781).
Test materials
Both interventions used a low-calorie fruit-flavored bev-
erage mix (provided by Mars, Inc.), standardized and
Fig. 2 a Study flow (CONSORT diagram) and b study protocol ll (RBC) deformability
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matched in composition. All beverage mixes were ag-
glomerated powders, utilizing a maltodextrin base into
which flavoring and sweeteners were incorporated. The
beverage mixes were provided in sachets (7 g, equals
one serving) labeled with an alphanumeric identifier to
enable a double-masked study design.
A high flavanol cocoa extract (Cocoapro®-processed
cocoa extract, Mars Inc.) was the source of flavanols in
the CF-containing drink. The CF-containing drink
(FLAVANOL) provided 450 mg of total cocoa flavanols
per serving (Adamson et al. 1999). The total amount of
CF in milligrams represents the sum of all monomeric
flavanols and their oligomers (i.e., procyanidins) with a
degree of polymerization up to and including 10 (i.e.,
DP 1–10). The predominant monomeric flavanol in this
drink was (−)-epicatechin (see Table 1).
The control beverage mix did not contain any cocoa
extract and thus provided 0 mg CF (CONTROL). Given
the natural presence of theobromine and caffeine in
cocoa extract, both theobromine and caffeine were
added to the control beverage mix in order to match
the composition of alkaloids in the CF-containing test
product. Coloring was also added so that the 0 mg CF
drink was also indistinguishable in appearance.
Compositional details for the 0 mg (CONTROL) and
450 mg CF (FLAVANOL) test drinks are provided in
Table 2.
Hemodynamic monitoring
Cardiac function was determined by heart rate (HR),
cardiac output (CO), stroke volume (SV), and total pe-
ripheral resistance (TPR); the function of major conduit
arteries, elastic aorta and muscular brachial artery, was
characterized based on their physicomechanical proper-
ties and capacity to dilate (Fig. 1). Physicomechanical
properties of the aorta are central blood pressure (BP),
pulse wave velocity (PWV), and augmentation index
(AIX); dilatory capacity of brachial artery was measured
by flow-mediated and nitroglycerin-mediated vasodila-
tion (FMD and NMD, respectively) as well as peripheral
blood pressure that was determined at the upper arm and
finger; the conductance function of arterioles was evalu-
ated as resting and maximal forearm blood flow (FBF)
during reactive hyperemia. Important readouts of micro-
vascular perfusion: Cutaneous perfusion was evaluated
by laser Doppler perfusion imaging (LDPI) at rest and
maximal perfusion during reactive hyperemia, and blood
rheology was determined as red blood cell (RBC)
deformability.
FMD
Brachial artery FMD and nitroglycerin-mediated vasodi-
lation (NMD)were measured by ultrasound (Vivid I, GE)
in combination with an automated analysis system
(Brachial Analyzer, MIA, Iowa City) as described
(Heiss et al. 2010a). Brachial artery (BA) FMD was
measured by ultrasound (10-MHz transducer; Vivid I,
GE) in combination with an automated analysis system
(Brachial Analyzer, MIA, Iowa City, IO) in a 21 °C-
temperature-controlled room after 15 min of supine rest.
Table 1 Baseline characteristics of study population (t test, mean
[SEM])
YOUNG ELDERLY p value
A n 22 20
Age (years) 26±1 60±2 <0.001
BMI (kg/m2) 24.9±0.5 26.5±0.7 0.013
Height (m) 1.83±0.01 1.81±0.01 0.453
Weight (kg) 81±2 88±3 0.079
Creatinine (mg/dl) 1.0±0.03 1·0±0.03 0.991
Total cholesterol (mg/dl) 172±7 207±7 <0.001
LDL cholesterol (mg/dl) 129±7 157±6 0.005
HDL cholesterol (mg/dl) 53±4 54±2 0.900
Triglycerides (mg/dl) 97±44 118±39 0.104
Fasting plasma glucose
(mg/dl)
89±2 95±2 0.027
HbA1c (%) 4.8±0.3 4.6±0.4 0.554
SBP (mmHg) 120±2 131±3 0.006
DBP (mmHg) 77±2 82±2 0.011
HR (bpm) 56±2 56±2 0.908
CRP (mg/dl) 0.1±0.03 0.1±0.03 0.692
Hb (mg/dl) 15.3±1.0 15.4±1.1 0.721
Leucocytes (1000/ul) 5.5±0.3 5.8±0.3 0.489
B Smoking history (n) 0 0
Medication (n) 0 0
Hx of CVD (n) 0 0
Diabetes mellitus (n) 0 0
Hypercholesterolemia (n) 0 6
Arterial hypertension (n) 0 4
SEM standard error of the mean, BMI body mass index, LDL low-
density lipoprotein, HDL high-density lipoprotein, SBP systolic
blood pressure, DBP diastolic blood pressure, HR heart rate, CRP
C-reactive protein, CVD cardiovascular disease
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Diameter and Doppler-flow velocity were measured at
baseline and immediately after cuff deflation, at 20, 40,
60, and 80 s, and maximal diameter was used to calculate
FMD. At the end of each study day, nitroglycerin-
mediated vasodilation (NMD) was measured at 4 min
after 400μg sublingual nitroglycerin (Nitrolingual, Pohl).
Hemodynamic monitoring
The Task Force Monitor (CN-Systems, Graz, Austria)
was used for continuous beat-to-beat assessment of
cardiovascular variables, including stroke volume, BP,
heart rate, and total peripheral resistance by impedance
cardiography, which included ECG, phonocardiogra-
phy, Finapres (Finapres-Medical-Systems, Amsterdam,
Netherlands), and BP monitoring system (Dynamap,
Tampa, USA).
BP measurements
Office blood pressure was measured three times after
10 min of rest using an automated clinical digital sphyg-
momanometer (Dynamap, Tampa, FL, USA) with ap-
propriately sized cuff placed around the upper arm at
heart level. Furthermore, we determined 24-h ambula-
tory BP measurements on the day before day 1 of the
study and during the last 24 h of the study on day 13
until the clinical visit on day 14. Values are expressed as
day, night, and total average. Furthermore, we deter-
mined BP at the fingertip using a tonometric device
(Finapres Medical Systems, Amsterdam, Netherlands).
Values were taken over 5 min and results represent
average of measurements taken. Central BP was derived
from peripheral pulse wave analysis obtained with
applanation tonometry using a proprietary transfer func-
tion (SphygmoCor®, AtCor medical, Australia).
Pulse wave analysis
Central blood pressure parameters including augmenta-
tion index (AIX) were measured by applanation tonom-
etry using the SphygmoCor® system. Via a transfer
function, the pressure waveform of the ascending aorta
was synthesized. PWV was determined from measure-
ments taken at the carotid and femoral artery as de-
scribed (Van Bortel et al. 2012).
Forearm blood flow
Forearm blood flow (FBF) was measured by mercury-
in-rubber strain gauge plethysmography (Periquant 833,
Gutman, Eurasburg, Germany) according to standard
techniques at rest and during reactive hyperemia sec-
ondary to 3 min of forearm ischemia.
Assessment of perfusion in cutaneous microcirculation
using laser doppler perfusion imaging
Perfusion of the cutaneousmicrocirculation of the forearm
skin was measured at rest and during reactive hyperemia
using a scanning laser Doppler perfusion imager
(PeriScan PIM III, Perimed, Sweden) as described
(Keymel et al. 2010). The parameter obtained is a global
circulatory index expressed in arbitrary units (au) integrat-
ing the multidirectional average velocities in skin resis-
tance arteries (lumen <100 m). After 15-min rest, the laser
beamwas positioned 15 cm above the forearm scanning a
field of 200 mm2 on the volar site of the forearm.
Microvascular reactivity was assessed during
postocclusive reactive hyperemia. Following the baseline
perfusion (1 min; 20 images), a blood pressure cuff locat-
ed at the proximal forearm was inflated to suprasystolic
pressure. After the cuff release, the microvascular re-
sponse on reactive hyperemia was recorded. Data acqui-
sition and analysis were performed by LDPIWin Software
Table 2 Composition of interventional vehicles ingested bi-daily
(ND = not detectable)
FLAVANOL CONTROL
Total cocoa flavanols (mg) 450 ND
Monomers (mg) 73 ND
(−)-Epicatechin (mg) 64 ND
(−)-Catechin (mg) 7 ND
(+)-Catechin (mg) 2 ND
(+)-Epicatechin (mg) ND ND
Dimers-decamers (mg) 377 ND
Theobromine (mg) 44 46
Caffeine (mg) 10 6
Fat (g) 0 0
Carbohydrates (g) 6 6
Protein (g) 0.1 0.1
Energy (kcal) 25 25
Sodium (mg) 3 3
Potassium (mg) 95 85
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(Perimed, Sweden). Maximum perfusion, amplitude of
perfusion (maximum perfusion − baseline perfusion), ra-
tio (maximum perfusion / baseline perfusion), percentage
increase ((maximum perfusion − baseline perfusion) /
baseline perfusion × 100), time to peak response, and area
under curve were evaluated without subtracting biological
zero from the data (Keymel et al. 2010).
Measurement of RBC deformability
RBC deformability was measured by a laser-assisted
optical rotational cell analyzer (LORCA, R&R
Mechatronics, Hoorn, Netherlands) according to the
manufacturers’ instructions as described (Keymel et al.
2011). After a 15-min rest in a supine position, blood
was drawn from the cubital vein, collected in a heparin-
ized tube (10 IE/ml, Liquemin 5000 IE, Roche,
Grenzach-Wyhlen, Germany), and RBC deformability
was measured by the laser-assisted optical rotational cell
analyzer (LORCA, R&R Mechatronics, Hoorn,
Netherlands) according to the manufactures’ instruc-
tions as described previously. Briefly, 20 μl of whole
blood was diluted 200 times in high-viscosity L–
polyvinylpyrrollidone. One milliliters of the suspension
was transferred into the LORCA device and automati-
cally subjected to varying degrees of shear stress at 0.3
to 10 Pa by stepwise increases of the rotation speed
(Keymel et al. 2011).
Analysis of flavanols and their metabolites in plasma
(−)-Epicatechin and its related metabolites where ana-
lyzed in plasma by HPLC-FLD/UVand electrochemical
detection using authentic standards provided by Mars
Inc., as previously described (Ottaviani et al. 2012).
Prior to analysis, plasma samples (0.5 ml) were
defrosted on ice and then subjected to β-glucuronidase
and sulfatase treatment (2000 units/ml; 40 min; 37 °C).
Then, samples were mixed with 2 ml of acidified ice-
cold methanol (0.5 % acetic acid in methanol, v/v)
containing 3′-O-ethyl-(−)-epicatechin (500 nM) as a
recovery standard. Samples were centrifuged at
17,000×g for 15 min at 4 °C, and the supernatant was
collected. The pellet was extracted again with 2 ml of
acidified ice-cold methanol (0.5 % acetic acid in meth-
anol, v/v) containing 3′-O-ethyl-(−)-epicatechin (500
nM), and then with 1 ml of 50 % methanol acidified
with 0.5 % acetic acid and containing 3′-O-ethyl-(−)-
epicatechin (500 nM). Combined supernatants
underwent concentration (to approximately 50 μl) using
a Speedvac system (Thermo Fisher Scientific Inc.,
Basingstoke, UK) and were mixed with resorcinol
(300 pmol) and catechol (300 pmol) prior to analysis
by HPLC. Flavanol monomers and O-methylated me-
tabolites were analyzed using a Hewlett-Packard 1200
series HPLC (Hewlett-Packard, Palo alto, CA, USA)
equipped with diode array and fluorescent detection.
Samples (50 μl) were injected onto a reversed-phase
Phenomenex Luna C18(2) column (4.6×150 mm) with
3-μm particle size. The mobile phase consisted of (A)
HPLC grade water, (B) 200mM sodium acetate, pH 4.4/
Methanol (84/16), and (C) acetonitrile, and the follow-
ing gradient protocol was run: 0 min, 75 % A, 25 % B;
5 min, 75 % A, 25 % B; 20 min, 65 % A, 25 % B;
28 min, 63 % A, 25 % B; 34 min, 55 % A; 25 % B;
41 min, 45 % A, 25 % B; 45 min, 25 % B, 75 % C;
55 min, 25% B, 75% C; 56.1 min 75%A, 25% B; and
60 min, 75 % A, 25 % B. The flow rate was 0.8 ml/min.
Detection of flavanols and their metabolites was per-
formed using a fluorescent detector with excitation
wavelength of 276 nm and emission wavelength of
316 nm. The concentration of each compound was
determined using an external calibration curve produced
with the use of authentic standards.
Statistical methods
Results are expressed as mean ± standard error of the
mean (SEM). Baseline data represent data of first visit
(day 1, 0 h). The primary test for an effect was a three-
way repeatedmixedmodel measurements ANOVA (one
within-subject factor: time [day 1, 0 h / day 1,1 h / day
14, 0 h / day 14, 1 h]; two between-subject factors: age
(YOUNG/ELDERLY) and intervention (CONTROL/
FLAVANOL). ANOVA and confidence intervals for
pairwise comparisons were computed with SPSS 20
(IBM). Correlations were Pearson’s r. Values of p less
than 0.05 were regarded as statistically significant.
Results
Baseline characteristics
A total of 60 male individuals underwent assessment for
eligibility [see CONSORT flow diagram (Fig. 2)]; 22
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young and 20 elderly subjects were included. None of
the participants had been previously diagnosed with, or
had clinical signs or symptoms of, cardiovascular dis-
ease, such as myocardial infarction, coronary artery
disease, hypertension, diabetes, or hyperlipidemia.
During the initial diagnostic workup, we observed mild
elevations of systolic blood pressure (n=4) and choles-
terol (n=6, see Table 1) in a few elderly individuals,
which were in a line with the diagnosis of mild isolated
systolic hypertension (grade 1) and hypercholesterol-
emia. Importantly, none of these mild alterations would
require medication according to current treatment guide-
lines (Perk et al. 2012). Compared to the YOUNG, the
ELDERLY exhibited statistically significantly greater
BMI, total- and LDL-cholesterol, fasting plasma glu-
cose, SBP, and diastolic blood pressure (DBP) at base-
line, but all these parameters were within limits consid-
ered normal, and none of the subjects had an indication
for medical treatment according to current guidelines.
The remaining demographic parameters did not signif-
icantly differ between groups (Table 1). All subjects
completed the study and all data were included in the
analysis. The test drinks were well tolerated and no
adverse events were reported.
Baseline hemodynamic characterization of aged
vasculature
At baseline on day 1, resting cardiac output was signif-
icantly lower in ELDERLY as compared to YOUNG
(6.4±0.2 and 5.2±0.3 l/min, p<0.05; Table 3). Given
that there was no difference in heart rate (57±3 and 57±
2 /min, p = n.s.), this was tenably driven by a signifi-
cantly lower stroke volume in the ELDERY (107±4 and
84±2 ml, p<0.05). Peripheral SBP (121±2 and 128±
2 mmHg, p<0.05) and DBP (76±2 and 81±2 ml,
p<0.05) as assessed by standard office measurement,
as well as total peripheral resistance (TPR), were signif-
icantly greater in ELDERLY. Similarly, greater values
were observed in 24-h ambulatory Holter monitoring
(continuous measurement over 5 min at the fingertip),
and central BP. ELDERLY participants exhibited stiffer
arteries with significantly greater pulse wave velocity
(PWV; 5.9±0.2 and 9.4±0.4 m/s, p<0.05) and aortic
augmentation index (AIX; −11±2 and 20±2 %,
p<0.05) as compared to YOUNG. Endothelium-
dependent and endothelium-independent conduit artery
vasodilator function, asmeasured by FMD (6.3±0.2 and
5.2±0.2 %, p<0.05) and nitroglycerin-mediated (NMD;
15.0±3 and 12.6±0.5 %, p<0.05), respectively, was
lower in the ELDERLY. The baseline diameter of the
brachial artery was greater in ELDERLY subjects (4.4±
0.1 and 4.8±0.2 mm, p<0.05). As detailed in Table 3,
resting forearm blood flow (FBF) and laser Doppler
perfusion, reflecting primarily skeletal muscle blood
flow (arteriolar cross-sectional area) and cutaneous cap-
illary perfusion, respectively, were similar between
YOUNG and ELDERLY. However, maximal hyper-
emic blood flow was lower in ELDERLY as compared
to that in YOUNG, suggesting a lessened functional
capacity to increase blood flow in response to ischemia.
Red blood cell (RBC) deformability was similar in
YOUNG and ELDERLY.
Flavanol intervention improves endothelial function
in YOUNG and ELDERLY
The FLAVANOL intervention led to an acute increase in
brachial artery FMD at 1 h after CF ingestion in both
YOUNG (6.1±0.2 to 7.4±0.2 %, p<0.05) and ELDE
Table 3 Summary of hemodynamic readouts (Mean [SEM])
Group
Intervention
Day
Hour
CO (l/min) 6.1 ± 0.4 5.8 ± 0.5 6.1 ± 0.2 6.2 ± 0.3 6.4 ± 0.2 6.3 ± 0.2 6.4 ± 0.2 6.0 ± 0.1 5.2 ± 0.3 § 4.9 ± 0.2 § 4.9 ± 0.2 § 5.0 ± 0.2 § 5.2 ± 0.3 § 5.0 ± 0.2 § 5.1 ± 0.1 § 4.7 ± 0.1 §
SV (ml) 107 ± 4 101 ± 7 111 ± 5 109 ± 6 109 ± 4 108 ± 7 108 ± 4 109 ± 4 82 ± 6 § 83 ± 6 § 80 ± 5 § 81 ± 5 § 84 ± 2 § 84 ± 3 § 83 ± 4 § 83 ± 4 §
Heart rate (/min) 57 ± 3 57 ± 2 58 ± 2 56 ± 2 59 ± 1 57 ± 2 60 ± 3 58 ± 3 56 ± 3 58 ± 2 58 ± 2 55 ± 3 57 ± 2 58 ± 1 59 ± 2 58 ± 2
TPR 1142 ± 71 1163 ± 100 1090 ± 47 1173 ± 64 1249 ± 28 940 ± 58 934 ± 86 944 ± 51 1781 ± 152 § 1763 ± 164 § 1812 ± 138 § 1784 ± 132 § 1901 ± 143 § 1527 ± 46 §*# 1485 ± 80 §*# 1473 ± 101 §*#
PWV (m/s) 5.9 ± 0.2 6.1 ± 0.2 5.8 ± 0.2 5.6 ± 0.1 6.0 ± 0.1 5.5 ± 0.2 *# 5.6 ± 0.1 *# 5.4 ± 0.2 *# 9.4 ± 0.4 § 9.5 ± 0.4 § 9.2 ± 0.3 § 9.2 ± 0.6 § 9.3 ± 0.5 § 8.6 ± 0.5 §*# 8.5 ± 0.4 §*# 8.2 ± 0.4 §*#
AIX (%) -10.9 ± 2.3 -9.6 ± 3.2 -7.9 ± 3.6 -12.2 ± 3.9 -3.5 ± 2.8 -10.0 ± 2.8 -5.5 ± 2.1 -7.6 ± 2.1 20.4 ± 2.1 § 19.4 ± 1.9 § 20.6 ± 2.8 § 18.2 ± 2.6 § 25.0 ± 2.6 § 18.9 ± 2.3 §*# 16.1 ± 1.9 §*# 13.8 ± 2.8 §*#
Central SBP (mmHg) 105 ± 2 104 ± 2 103 ± 2 101 ± 2 104 ± 3 102 ± 3 103 ± 4 104 ± 3 122 ± 2 § 121 ± 3 § 119 ± 4 § 118 ± 3 § 127 ± 6 §*# 123 ± 6 §*# 120 ± 5 §*# 120 ± 4 §*#
Central DBP (mmHg) 78 ± 2 77 ± 2 76 ± 3 75 ± 2 78 ± 2 75 ± 2 *# 73 ± 2 *# 72 ± 2 *# 80 ± 2 § 80 ± 1 § 79 ± 1 § 81 ± 1 § 87 ± 3 §*# 83 ± 3 §*# 80 ± 3 §*# 82 ± 3 §*#
BA diameter (mm) 4.4 ± 0.1 4.4 ± 0.1 4.5 ± 0.1 4.0 ± 0.4 4.4 ± 0.1 4.4 ± 0.1 4.0 ± 0.4 4.4 ± 0.1 4.8 ± 0.2 § 4.8 ± 0.2 § 4.8 ± 0.2 § 4.8 ± 0.1 § 5.0 ± 0.9 § 4.9 ± 0.2 § 5.0 ± 0.2 § 5.0 ± 0.2 §
FMD (%) 6.3 ± 0.2 6.2 ± 0.2 6.0 ± 0.2 6.3 ± 0.2 6.1 ± 0.2 7.4 ± 0.2 *# 7.8 ± 0.2 *# 7.8 ± 0.1 *# 5.2 ± 0.3 § 5.2 ± 0.32 § 5.0 ± 0.3 § 4.9 ± 0.3 § 4.9 ± 0.2 § 5.9 ± 0.2 §*# 6.3 ± 0.3 §*# 6.3 ± 0.2 §*#
NMD (%) 15.0 ± 0.3 15,3 ± 0,3 14.7 ± 0.5 15.0 ± 0.4 12.6 ± 0.5 § 13.7 ± 0.6 § 13.0 ± 0.6 § 13.9 ± 0.3 §
Office SBP (mmHg) 121 ± 2 119 ± 2 118 ± 2 119 ± 3 122 ± 1 122 ± 1 119 ± 2 120 ± 2 128 ± 2 § 127 ± 3 § 126 ± 3 § 125 ± 3 § 134 ± 4 § 129 ± 4 §*# 128 ± 3 §*# 127 ± 3 §*#
Office DBP (mmHg) 76 ± 2 77 ± 2 73 ± 3 75 ± 2 78 ± 2 72 ± 2 *# 71 ± 2 *# 73 ± 2 *# 81 ± 2 § 79 ± 2 § 77 ± 2 § 78 ± 2 § 83 ± 3 § 78 ± 3 §*# 77 ± 3 §*# 76 ± 3 §*#
24 h SBP (mmHg) 126 ± 2 125 ± 3 128 ± 3 124 ± 4 134 ± 2 § 133 ± 3 § 135 ± 3 § 130 ± 2 §#
24 h DBP (mmHg) 76 ± 2 77 ± 2 77 ± 1 73 ± 3 # 86 ± 2 § 86 ± 2 § 91 ± 3 § 84 ± 3 §#
Finger SBP (mmHg) 114 ± 2 115 ± 2 112 ± 2 114 ± 2 114 ± 4 112 ± 4 111 ± 4 111 ± 4 125 ± 3 § 126 ± 2 § 124 ± 3 § 124 ± 2 § 127 ± 5 § 120 ± 4 §*# 116 ± 4 §*# 119 ± 4 §*#
Finger DBP (mmHg) 72 ± 2 72 ± 2 69 ± 2 71 ± 1 71 ± 2 66 ± 1 *# 64 ± 3 *# 64 ± 2 *# 82 ± 2 § 82 ± 2 § 79 ± 2 § 80 ± 2 § 84 ± 3 § 76 ± 3 §*# 72 ± 3 §*# 72 ± 3 §*#
FBF baseline (ml/100 ml*min) 1.5 ± 0.1 1.5 ± 0.1 1.5 ± 0.1 1.4 ± 0.1 1.7 ± 0.1 1.6 ± 0.1 1.6 ± 0.1 1.6 ± 0.1 1.1 ± 0.0 0.9 ± 0,1 0.8 ± 0.0 0.9 ± 0,0 1.5 ± 0.1 1.2 ± 0.1 1.1 ± 0.1 1.1 ± 0.0
FBF maximal (ml/100 ml*min) 13.7 ± 1.6 14.3 ± 1.8 13.7 ± 1.7 13.8 ± 1.5 13.2 ± 0.6 16.2 ± 1.0 *# 16.9 ± 0.6 *# 16.9 ± 1.1 *# 11.3 ± 1.2 § 10.8 ± 1.5 § 11.6 ± 1.7 § 11.0 ± 1.5 § 10.9 ± 1.2 § 12.3 ± 1.5 §*# 14.0 ± 1.4 §*# 13.9 ± 1.1 §*#
LDPI baseline (PU) 42 ± 1 42 ± 1 42 ± 1 39 ± 1 38 ± 1 40 ± 1 39 ± 1 40 ± 1 41 ± 1 44 ± 0 39 ± 1 40 ± 1 38 ± 1 39 ± 1 40 ± 1 39 ± 1
LDPI max (PU) 259 ± 15 270 ± 17 260 ± 22 258 ± 17 257 ± 14 292 ± 15 *# 307 ± 14 *# 296 ± 17 *# 186 ± 5 § 186 ± 8 § 178 ± 5 § 180 ± 5 § 184 ± 15 § 200 ± 14 §*# 214 ± 12 §*# 213 ± 12 §*#
RBC deformability 0.334 ± 0.011 0.326 ± 0.010 0.329 ± 0.007 0.329 ± 0.009 0.327 ± 0.008 0.334 ± 0.008 *# 0.332 ± 0.008 *# 0.336 ± 0.010 *# 0.321 ± 0.006 0,323 ± 0.007 § 0.319 ± 0.005 § 0,321 ± 0.007 § 0.325 ± 0.007 § 0.334 ± 0.009 §*# 0.341 ± 0.007 §*#0.341 ± 0.007 §*#
0 10 1 0 1 0 1
1 14
0 1 0 1 0 1 0 1
1 14 1 14 1 14
YOUNG ELDERLY
CONTROL FLAVANOL CONTROL FLAVANOL
p<0.05 versus individual baseline (day 1, 0 h); § p<0.05 versus YOUNG at the same time point and the same intervention group; # p<0.05
versus CONTROL in the same age group
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RLY (4.9±0.2 to 5.9±0.2 %, p<0.05; Table 3). FMD
after overnight fast (0 h) on day 14 was higher in both
groups (7.8±0.2 and 6.3±0.3 %, p<0.05) as compared
to that on study day 1 (0 h). Additional acute ingestion
of FLAVANOL did not further increase endothelial
function assessed at 1 h on day 14. Despite differences
in baseline FMD, it is noteworthy that each individual
exhibited positive responses following FLAVANOL in-
take. The mean changes in FMD following FLAV
ANOL were 1.3±0.6 % in the young and 1.0±0.6 %
in the elderly at 1 h and 1.6±0.8 % in the young and 1.4
±0.7 % in the elderly at 14 days. To evaluate determi-
nants of inter-individual response, we correlated the
change in FMD at 1 h and 14 days with baseline epide-
miological parameters (age, height, weight, BMI, total
cholesterol, LDL, HDL, office SBP, office DBP). This
analysis showed that none of these parameters correlat-
ed with changes in FMD. The baseline diameter of the
brachial artery and NMD remained unaffected by either
FLAVANOL or CONTROL.
Flavanol intervention decreases SBP in ELDERLY
and this is linked to decreased arterial stiffness
and augmentation index
As depicted in Table 3, our results show that FLAV
ANOL, but not CONTROL, led to a significant acute
decrease in PWVin ELDERLY (9.3±0.5 to 8.6±0.5 m/s,
p<0.05) and YOUNG (6.0±0.1 to 5.5±0.2 m/s, p<0.05)
and that PWVremained decreased at 0 h on day 14 (5.6±
0.1 and 8.5±0.4 m/s, p<0.05) and did not further de-
crease at 1 h after FLAVANOL drink at day 14.
Importantly, FLAVANOL only decreased office periph-
eral SBP (acute, −5 mmHg; chronic, −6 mmHg; p<0.05)
and AIX (acute, −6 %; chronic, −7 %; p<0.05) in
ELDERLY, and this was detectable at all time points
investigated as compared to day 1, 0 h. Notably, this
decrease in SBP was confirmed by 24-h ambulatory
monitoring and central blood pressure measurements.
We found a significant correlation between the chang-
es in SBP and AIX after FLAVANOL (r=0.77,
p=0.009). It is known that part of the PWV can be
modulated by endothelial function. It is noteworthy
that the changes in PWV showed a close correlation
with improvements in FMD at day 14 (r=−0.56,
p=0.01), thereby corroborating a mechanistic link
between increases in endothelial function and a de-
crease in SBP in ELDERLY subjects.
Flavanol intake decreases systemic vascular resistance
As detailed in Table 3, following acute consumption of
FLAVANOL, DBP and TPR significantly decreased in
both groups, and both parameters remained decreased at
day 14, whereas cardiac hemodynamics—cardiac out-
put, heart rate, and stroke volume—were not affected.
At all time points after ingestion of FLAVANOL, qual-
itatively identical changes were observed in DBP on the
level of central, brachial artery, and finger BP. These in-
office measurements were confirmed by 24-h ambula-
tory BP monitoring. No significant effects were ob-
served after CONTROL drink. An increased maximal
FBF in both groups suggests a functional improvement
in arteriolar blood flow capacity. A significant univariate
correlation existed between DBP decrease and increase
in maximal FBF(r=−0.6, p=0.01). This suggests that
the FLAVANOL intervention acted primarily on the
vascular and not the cardiac component of systemic
hemodynamics.
FLAVANOL intervention decreases RBC deformability
RBC deformability increased after FLAVANOL inter-
vention in both YOUNG and ELDERLY. This was
paralleled by significantly increased maximal perfusion
of the cutaneous capillaries as measured by laser
Doppler during reactive hyperemia. Significant univar-
iate correlation existed between the increase in maximal
perfusion and RBC deformability (r=0.6, p=0.01).
Levels of structurally related flavanol metabolites
At the baseline visit, only low levels of total plasma
flavanols were detected (YOUNG, 21±2 nM; ELDE
RLY, 32±2 nM). At 1 h (day 1) after acute consumption
of FLAVANOL, but not CONTROL, both, YOUNG
and ELDERLY, showed significantly increased levels
of plasma flavanols (668±19 and 704±29 nM, respec-
tively; p<0.0001 with respect to baseline; p>0.05 be-
tween young and elderly). After 14 days of two-times-
daily CF consumption and following overnight fasting,
baseline levels remained significantly higher as com-
pared to those on day 1. Additional acute ingestion of
FLAVANOL led to flavanol plasma levels of 745±21
and 857±50 nM (p<0.0001 vs. baseline day 14) in
YOUNG and ELDERLY, respectively, but these levels
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were not significantly different from values observed
after acute ingestion on day 1.
Discussion
The FLAVIOLA AGE study is the first study specifically
intended to investigate CF-associated improvements of
hallmarks of cardiovascular aging, on the level of car-
diac performance, endothelial dysfunction, increased
systolic blood pressure, vascular stiffness, and microcir-
culatory functions. The outcomes demonstrate how a
CF-based dietary intervention affects the cardiovascular
system and reverses age-related increases of blood pres-
sure together with vascular stiffness in healthy elderly
humans. CF-intake-associated improvements in the
compliance of large arteries were accompanied by a
lowered pulse wave velocity and decreased aortic aug-
mentation of systolic blood pressure. Endothelial func-
tion in large conduit arteries was significantly improved
in healthy young and elderly individuals. These benefi-
cial effects were associated with an improved dilatory
capacity of resistance arteries, decreased diastolic blood
pressure, and increases in microcirculatory perfusion
and red blood cell deformability. These CF-intake-
mediated modulations of circulatory function were in-
dependent of changes in cardiac performance, since
cardiac output was not affected by CF (Table 3).
CF intake improves endothelial function in young
and elderly
Consistent with previous studies in other populations,
ELDERLY exhibited significantly decreased
endothelium-dependent vasodilation at baseline as com-
pared to YOUNG (Heiss et al. 2005). So far, no study
has specifically investigated the vascular effects of CF in
healthy elderly and compared it to young individuals.
CF-intake-related improvements in FMD occurred
acutely following intake but, more importantly, were
also manifest when comparing baseline FMD (fasted;
0 h) on days 1 and 14.Moreover, and despite differences
in baseline FMD, our results show that the absolute
effect size of FMD improvements was similar in young
and elderly healthy men. It is also noteworthy that the
bioavailability of flavanols in the healthy young men
was comparable to that in elderly individuals, as evi-
denced by flavanol plasma concentrations.
CF intake attenuates age-related increase in blood
pressure and arterial stiffness
Our results show that the CF-intake-dependent de-
crease in BP in ELDERLY was selective to SBP
(Table 3). An endothelial function increase along with
a decrease in PWV was also present in the YOUNG,
but as would be expected from the initial absence of
BP augmentation in this group, these changes did not
result in a modulation of SBP. A similar relationship
between baseline BP and the effect size of BP-
lowering therapeutic agents, which is in a similar
range as shown here for flavanols, has been reported
for various drugs, including ACE inhibitors
(O’Rourke and Hashimoto 2007). Tenable explana-
tions of how flavanols could affect age-related chang-
es in SBP and PWV may be found in the observation
of improved compliance due to improved endothelial
function as well as decreases in DBP, and thus chang-
es in the distal reflection point of the pulse wave.
CF intake decreases diastolic blood pressure
and increases conductance of small arteries
We observed significant decreases in DBP and also in
TPR in both young and elderly participants. CFs (30–
1080 mg total flavanols per day) have been shown to
elicit a small, but significant DBP-reducing effect of
−2.2 mmHg in a meta analysis of a heterogeneous study
population including patients with and without CVD
(Ried et al. 2012). Resistance to blood flow is principal-
ly mediated by arteriolar diameter, which is modified by
arteriolar vasoconstriction and dilation, respectively. We
observed a significant increase in the maximal forearm
blood flow and cutaneous perfusion during reactive
hyperemia. This suggests that CF intake may increase
not only the dilatory function of conduit arteries but also
that of the arterioles. This effect, together with the
increased RBC deformability, contributes to the en-
hanced perfusion of the microcirculation observed fol-
lowing CF intake. Mechanistically, CF-related vascular
effects have been linked to an increase in nitric oxide
synthase (NOS) activity (Del Rio et al. 2013; Schroeter
et al. 2006). RBCs have been demonstrated to express a
functional eNOS that may modulate RBC deformability
independent of vascular tone (Cortese-Krott et al. 2012;
Horn et al. 2011). Consequently, our current data sup-
port the supposition that CF intake improves tissue
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perfusion, at least in part, by increasing dilatory capacity
of arterioles and increasing RBC deformability.
The FLAVIOLA AGE study and healthy vascular aging
Aging is considered to be an independent cardiovascular
risk factor in most methods of CV risk scoring. This
raises the important question as to whether or not the
regular intake of vasculoprotective bioactives not only
does reverse age-associated changes of circulatory func-
tion but also has the potential to maintain vascular
function with increasing age. It is tempting to speculate
that such an approach may ultimately support healthy
vascular aging, extend the healthy life span, and lead to
a lower rate of cardiovascular events. While such a
proposition could only be finally verified through
long-term longitudinal studies in healthy elderly indi-
viduals, it is possible to meaningfully advance our un-
derstanding of this question by way of smaller-scale
investigations like the FLAVIOLA AGE study, which
can provide the necessary basis for larger-scale studies
in future. The present study extended our knowledge
regarding the potential role of CF intake in the mainte-
nance of optimal cardiovascular function during normal
aging. We demonstrated here that CF intake is effective
not only in healthy young but also in elderly individuals,
as evidenced by the CF-related reversal of age-specific
alterations in circulatory function, vascular stiffness, and
hemodynamics.
Limitations
Intending to specifically focus on mechanistic aspects in
greater detail than can be done practically in a larger-
scale and longer-term study, the duration of this study
was chosen to be 2 weeks. This is based on the outcomes
of our previous work showing that approximately
2 weeks of CF intake at 450 mg two times daily is
sufficient to establish maximal and sustained improve-
ments (plateau) in FMD in this study population.
Consequently, it can be argued tenably that despite of
limitations with regard to study duration, our data are
relevant in furthering understanding of pharmacody-
namics aspects of CF-mediated changes in endothelial
function, cardiac output, conductance of conduit and
resistance arteries, and perfusion in the microcirculation.
An additional limitation regarding the design of this
study is the exclusion of female participants. The ratio-
nale for doing so was based on complexities related to
the influence on FMD and other cardiovascular readouts
of hormonal changes that occur in women during the
menstrual cycle and during peri-menopause and meno-
pause. To assess detailed mechanistic aspects of CF-
intake-related changes in cardiovascular function over
the background of menstrual-cycle-dependent modula-
tions, it will require a specific and comprehensive study
design, which was beyond the scope of this investiga-
tion. Finally, the elderly subjects in our study presented
with significantly lower cardiac output as compared to
the young subjects that was not significantly changed by
the flavanol intervention. It has been appreciated for a
long time that besides stiffening of the arteries, stiffen-
ing of the heart occurs with advancing age (Tresch and
McGough 1995), leading to diastolic dysfunction
(Upadhya et al. 2015). Whereas a lack of flavanol-
related effects on cardiac output may be interpreted as
a lack of major flavanol effect on cardiac function, more
detailed studies with echocardiography and potentially
spiro-ergometry are needed to investigate the impact of
flavanols on diastolic function and cardiac performance
capacity.
Conclusions
A CF-based dietary intervention in elderly individuals
decreases systolic blood pressure and improves vascular
stiffness. These beneficial effects are associated with
improved endothelial function in large arteries and en-
hanced vasodilator function in resistance arteries, as
well as with improved microcirculatory perfusion that
can already be observed in young healthy participants.
Our findings provide clear evidence and novel insights
that scientifically underpin the potential of dietary CF to
reverse, or at least to attenuate, features of circulatory
dysfunction associated with vascular aging in healthy
men, a major contributor to atherogenic risk indepen-
dent of numeric age.
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